Ophidion’s CNS Carrier Technology (OCCT) Derived Programs
Ophidion is addressing the problem of drug delivery into the CNS with an innovative and patented blood-brain-barrier traversing technology with proven preclinical proof-of-concept in animal models of cognition and pain. Multiple programs could potentially enter into the clinic in the next 2-3 years, addressing significant unmet needs in rare diseases as well as large markets. These include diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease), Huntington’s disease (HD), and Analgesia (an opioid-sparing approach to treat nociceptive pain).